GlobeNewswire Inc | Sep 8, 2020 07:00AM EDT

September 08, 2020

BURLINGAME, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., President and Chief Executive Officer and other senior executives, will participate in two upcoming virtual investor conferences in September:

Cantor Virtual Healthcare Conference Format: Fireside chat with Alethia Young, Director of ResearchDate: Tuesday, September 15, 2020Time: 1:20 PM Eastern TimeWebcast link: Available here

H.C. Wainwright 22nd Annual Global Investment ConferenceFormat: Corporate Presentation Date: Wednesday, September 16, 2020Time: 2:30 PM Eastern TimeWebcast link: Available here

Company management will also be participating in one-on-one investor meetings at both conferences.

A live webcast of the events can also be accessed by visiting the Investors section of ALX Oncologys website at www.alxoncology.com and selecting the Investor Calendar under the News & Events tab. A replay of the webcasts will be archived for up to 90 days following the presentation dates.

About ALX Oncology

ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncologys lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to advance ALX148 into clinical development for the treatment of myelodysplastic syndromes and to continue clinical development for the treatment of a range of solid tumor indications.

Investor Contact:

Peter GarciaChief Financial Officer, ALX Oncology(650) 466-7125 Ext. 113peter@alxoncology.com

Argot Partners(212)-600-1902alxoncology@argotpartners.com

Media Contact:

Karen SharmaMacDougall(781) 235-3060alx@macbiocom.com